Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Liam Mulroy is active.

Publication


Featured researches published by Liam Mulroy.


Radiation Oncology | 2011

PET/CT aids the staging of and radiotherapy planning for early-stage extranodal natural killer/T-cell lymphoma, nasal type: A case series

Shannon L MacDonald; Liam Mulroy; Derek Wilke; Steven Burrell

Extranodal natural killer/T-cell lymphoma (ENKTL), nasal type, is a rare form of non-Hodgkin lymphoma. Treatment of ENKTL primarily relies on radiation; thus, proper delineation of target volumes is critical. Currently, the ideal modalities for delineation of gross tumor volume for ENKTL are unknown. We describe three consecutive cases of localized ENKTL that presented to the Nova Scotia Cancer Centre in Halifax, Nova Scotia. All patients had a planning CT and MRI as well as a planning FDG-PET/CT in the radiotherapy treatment position, wearing immobilization masks. All patients received radiation alone. In two patients, PET/CT changed not only the stage, but also the target volume requiring treatment. The third patient was unable to tolerate an MRI, but was able to undergo PET/CT, which improved the accuracy of the target volume. PET/CT aided the staging of and radiotherapy planning for our patients and appears to be a promising tool in the treatment of ENKTL.


Medical Physics | 2016

Sci-Fri PM: Radiation Therapy, Planning, Imaging, and Special Techniques - 07: Transitioning from extended-distance total body irradiation to optimized VMAT total marrow irradiation

Amanda Cherpak; Krista Chytyk-Praznik; Mammo Yewondwossen; Jason Schella; Carol-Anne Davis; Allan Day; Jennifer DeGiobbi; Dave McAloney; Liam Mulroy

Purpose: TMI targets only the bone marrow, with the intent of sparing normal tissues. The NSCC has recently implemented a TMI protocol which includes VMAT fields to treat the bone marrow from head to mid-thigh and extended SSD POP fields to treat the lower legs. This work describes the commissioning and initial clinical results of the first reported VMAT TMI treatments in Canada. Methods: Detailed CT simulation, imaging, planning and treatment procedures were developed by a multi-disciplinary team. Patients have 1 cm of bolus over the lower legs and 0.5 cm of bolus around the lower arms. The PTV includes all bone, except mandible, facial bones and hands, with the objective of V(12 Gy) > 90%. Detailed analysis of the influence of field overlap was performed to determine optimal field placement and image-guidance tolerances. Results: PTV coverage was achieved for all cases as V(12 Gy) ranged from 90.4–96.3%. The minimum dose to the PTV, D(99%), ranged from 91.4–97.87% and V(90%Rx=10.8 Gy) ranged from 99.1–100.0%. The lungs, liver and heart had an average Dmean of (7.8±0.3)Gy/(65±2)%, (7.6±0.7)Gy/(63±5)%, and (6.8±0.4)Gy/(56±4)% respectively. Conclusions: Commissioning required input and collaboration from all team members. Transitioning from TBI to TMI requires additional time for contouring, treatment planning, QA, and treatment. Patient benefit can however be seen in the quality of OAR sparing.


Journal of Applied Clinical Medical Physics | 2018

Energy‐dependent OAR sparing and dose conformity for total marrow irradiation of obese patients

Amanda Cherpak; Thalat Monajemi; Krista Chytyk‐Praznik; Liam Mulroy

Abstract Purpose To investigate the effect on target coverage and organs at risk sparing by using 10 versus 6 MV for VMAT total marrow irradiation of obese patients. Methods and Materials Twenty‐six total marrow irradiation, TMI, treatment plans delivered between December 2014 and June 2017 were reviewed and 10 were chosen for replanning based on patient characteristics and plan metrics. Beam geometry and isocenter placement were conserved, energy was changed from 6 to 10 MV and plans were reoptimized. Resulting dose distributions were compared to original plans to evaluate any potential advantage of choosing one energy over the other. Results Target coverage and total monitor units were consistent between the 6 and 10 MV plans when averaged over all ten patients. Improvement in the conformity index (−11.0%, P = 0.009) when using 10 MV was statistically significant compared to the 6 MV plans. Volumes of normal tissue receiving 50%, 75%, and 90% Rx all decreased for the 10 MV plans compared to the original 6 MV plans. The mean dose to individual OARs decreased significantly for all investigated structures except for the lenses, oral cavity, and genitalia. The largest decreases in Dmean were found for the rectum (22.4%, P = 0.004) and bladder (18.1%, P = 0.005). The three highest priorities for sparing during plan optimization (lungs, liver, and heart), showed decreases of 7.6%, 16.1%, and 13.0%. Conclusions Use of a higher energy 10 MV beam provided similar dose to target while achieving increased OAR and normal tissue sparing for the patients reviewed in this study.


Journal of Medical Imaging and Radiation Sciences | 2015

Investigating the Impact of Positron Emission Tomography–Computed Tomography Versus Computed Tomography Alone for High-risk Volume Selection in Head and Neck and Lung Patients Undergoing Radiotherapy: Interim Findings

Carol-Anne Davis; Christopher G. Thomas; Mohamed Abdolell; Allan Day; Helmut Hollenhorst; Murali Rajaraman; Liam Mulroy; David Bowes; Slawa Cwajna; Dorianne Rheaume; Nikhilesh Patil; Steven Burrell; Derek Wilke


International Journal of Radiation Oncology Biology Physics | 2005

Validation of Planned Surface and Build-Up Dose in Head and Neck Intensity Modulated Radiation Therapy

K.J. Hirmiz; James L. Robar; Murali Rajaraman; Liam Mulroy; Derek Wilke


Radiotherapy and Oncology | 2016

216: Surface Dosimetry of Patients Undergoing Total Body Irradiation (TBI): A Retrospective Analysis for Quality Assurance

Arpita Sengupta; Derek Wilke; Amanda Cherpak; Krista Chytyk-Praznik; Jason Schella; Mammo Yewondwossen; James Allan; Liam Mulroy


International Journal of Radiation Oncology Biology Physics | 2016

Incidence of Brain Metastases and Outcomes in Pulmonary Large Cell Neuroendocrine Carcinoma.

Y. Zhao; David Bowes; M. Castonguay; Z. Xu; M. Plourde; Liam Mulroy; M. MacNeil; R. Dewar


Dalhousie Medical Journal | 2015

An unusual case of intrathoracic Castleman’s Disease

Rachel Schoon; Liam Mulroy; Zhaolin Xu; Drew Bethune


International Journal of Radiation Oncology Biology Physics | 2012

A Population-based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in a Canadian Province

G. Bahl; K. Tennessen; A. Mahmoud-Ahmed; Dorianne Rheaume; I. Fleetwood; Liam Mulroy


Radiotherapy and Oncology | 2006

80 Stereotactic radiotherapy in the treatment of meningioma: A dose-fall-off study

C.M. Pochini; Liam Mulroy; J. Robar; Derek Wilke; I. Fleetwood; D. Rheaume; J. Schella; Mammo Yewondwossen; R. Young

Collaboration


Dive into the Liam Mulroy's collaboration.

Top Co-Authors

Avatar

Derek Wilke

Queen Elizabeth II Health Sciences Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jason Schella

Princess Margaret Cancer Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge